Impact of Conventional Treatments and Clinical Variables on Thyroid Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Thyroid Cancer. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Retrospective and Prospective Evaluation of the Impact of Innovative and Conventional Treatments and of Clinical Variables on the Outcome of Thyroid Cancer
Overview
DTC has a generally favorable prognosis. The possibility to discriminate between patients with aggressive tumors and those with a more indolent behavior may reduce the need for unnecessary treatments. Aim of this observational study is to evaluate how anamnestic, clinical, and histopathological variables may influence the outcome of the enrolled patients, both regarding morbidity and mortality and in terms of therapeutic choices. The study aims to evaluate the prognostic impact of the therapeutic interventions in terms of efficacy and regarding the appearance of adverse events.
Primary outcome measures
- Dynamic risk stratification [Time frame: one year from the primary treatment]
- Dynamic risk stratification [Time frame: five years from the primary treatment]
- Dynamic risk stratification [Time frame: ten years from the primary treatment]
- Progression-free survival [Time frame: one year from the primary treatment]
- Progression-free survival [Time frame: five years from the primary treatment]
- Progression-free survival [Time frame: ten years from the primary treatment]
- Overall survival [Time frame: one year from the primary treatment]
- Overall survival [Time frame: five years from the primary treatment]
- Overall survival [Time frame: ten years from the primary treatment]
Eligibility criteria
Inclusion criteria
\- thyroid cancer diagnosis
Exclusion criteria
- patients unable to sign informed consent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
Italy · 1 center
- Istituto Auxologico Italiano, IRCCS — Milan
Identifiers
NCT: NCT05752604 · 05C212